Overview

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Status:
Completed

Trial end date:
2014-07-01

Target enrollment:

Participant gender:

Summary

The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting multiple sclerosis. The secondary study objectives are to test the superiority of DAC HYP compared to IFN β-1a in slowing functional decline and disability progression and maintaining quality of life in this participant population.

Phase:

Phase 3

Details

Lead Sponsor:

Biogen

Collaborator:

AbbVie

Treatments:

Daclizumab
Immunoglobulin G
Interferon beta-1a
Interferon-beta
Interferons